Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with our peers we work towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/21/20 | $32,500,000 | Series A |
Aisling Capital BVF Partners Driehaus Capital Management Qiming Venture Partners Vertex Ventures | undisclosed |
| 11/18/20 | $65,000,000 | Series B |
Aisling Capital BVF Partners Cormorant Asset Management Driehaus Capital Management Janus Henderson Investors Qiming Venture Partners Samsara BioCapital VenBio Vertex Ventures Vivo Capital | undisclosed |
